Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 8/20 | 0.42 |
| ▸ | BRAF | P15056 | 4/20 | 0.42 |
| ▸ | UBE2M | P61081 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | WRN | Q14191 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29621642 | 0.85 | NPC1 (0.45) | KMT2A | |
| SCHEMBL16670995 | 0.84 | GAA (0.46) | GRM4KDRBLM | |
| SCHEMBL9892929 | 0.84 | AR (0.49) | ARGRM4TAS1R3TAS1R1TAS1R2 | |
| Hydrochloric Acid SCHEMBL29621767 | 0.83 | GAA (0.45) | GRM4KDRBLM | |
| SCHEMBL22644365 | 0.83 | KMT2A (0.52) | KMT2A | |
| SCHEMBL24515714 | 0.83 | AR (0.51) | ARGRM4TAS1R3TAS1R1TAS1R2 | |
| Hydrochloric Acid SCHEMBL29621649 | 0.82 | KMT2A (0.51) | KMT2A | |
| Hydrochloric Acid SCHEMBL29621803 | 0.81 | IDO1 (0.41) | KDRKMT2A | |
| SCHEMBL22644329 | 0.80 | GRM4 (0.45) | GRM4KMT2ABLMWRN | |
| SCHEMBL29458395 | 0.80 | GRM4 (0.45) | GRM4KMT2ABLMWRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200352925-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-12 | — | — | US | disclosed |
| WO-2020225230-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352925-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | HDGF, FABP1, NR1H4 | AR 3755/4885GRM4 3675/4885TAS1R3 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.